Skip to content

Scholar Rock SRRK Free cash flow

Free cash flow at other companies

Biogen logo
BiogenBIIB
$594.3M+167%
PTC Therapeutics logo
PTC TherapeuticsPTCT
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Arrowhead Research logo
Arrowhead ResearchARWR
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%

Valuation

See full
Market cap$5.67B+85.5%
Enterprise value$5.45B+82.6%
P/S170.9×

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Calculated from Scholar Rock’s reported figures.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's free cash flow?
Scholar Rock (SRRK) reported free cash flow of -$82.17M in Q1 2026.
How has Scholar Rock's free cash flow changed year-over-year?
Scholar Rock's free cash flow decreased by 4.1% year-over-year, from -$78.95M to -$82.17M.
What is the long-term trend for Scholar Rock's free cash flow?
Over 4 years (2021 to 2025), Scholar Rock's free cash flow has grown at a 22.8% compound annual growth rate (CAGR), from -$132.04M to -$300.64M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.